Atossa Genetics(ATOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ATOS Atossa Genetics

Market Closed 04-24 16:00:00 EDT

5.70

-0.03

-0.52%

盘后5.75

+0.05+0.91%

16:33 EDT

High5.80	Low5.54	Vol42.68K
Open5.73	D1 Closing5.73	Amplitude4.54%
Mkt Cap49.09M	Tradable Cap49.06M	Total Shares8.61M
T/O242.11K	T/O Rate0.50%	Tradable Shares8.61M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ATOS","market":"US","secType":"STK","nameCN":"Atossa Genetics","latestPrice":5.7,"timestamp":1777060800000,"preClose":5.73,"halted":0,"volume":42677,"hourTrading":{"tag":"盘后","latestPrice":5.7521,"preClose":5.7,"latestTime":"16:33 EDT","volume":312,"amount":1794.27,"timestamp":1777062797358,"change":0.0521,"changeRate":0.00914,"amplitude":0.00914},"delay":0,"changeRate":-0.0052356020942408805,"floatShares":8606660,"shares":8611428,"eps":-4.04,"marketStatus":"Market Closed","change":-0.03,"latestTime":"04-24 16:00:00 EDT","open":5.73,"high":5.8,"low":5.54,"amount":242111.87027100002,"amplitude":0.045375,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.04,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1777276800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1352350800000,"exchange":"NASDAQ","adjPreClose":5.73,"preHourTrading":{"tag":"盘前","latestPrice":5.7254,"preClose":5.73,"latestTime":"09:26 EDT","volume":206,"amount":1179.8200096,"timestamp":1777037166979,"change":-0.0046,"changeRate":-0.000803,"amplitude":0.013019},"postHourTrading":{"tag":"盘后","latestPrice":5.7521,"preClose":5.7,"latestTime":"16:33 EDT","volume":312,"amount":1794.27,"timestamp":1777062797358,"change":0.0521,"changeRate":0.00914,"amplitude":0.00914},"volumeRatio":0.6034124498473072,"impliedVol":0.4098,"impliedVolPercentile":0.112},"requestUrl":"/m/hq/s/ATOS/wiki","defaultTab":"wiki","newsList":[{"id":"2627739218","title":"Atossa Therapeutics - Co, Intas Pharmaceuticals, Jina Pharmaceuticals Agree Not to Challenge Specified Endoxifen-Related Patents - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2627739218","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627739218?lang=en_us&edition=fundamental","pubTime":"2026-04-16 20:33","pubTimestamp":1776342828,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nFWN40Z0UP:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627218736","title":"Atossa Therapeutics - Parties Agree to Seek Termination of Ptab Proceedings - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2627218736","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627218736?lang=en_us&edition=fundamental","pubTime":"2026-04-16 20:33","pubTimestamp":1776342828,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nFWN40Z0UP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627218053","title":"Atossa Therapeutics - Two Endoxifen Patents Expected to Remain Issued and Enforceable - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2627218053","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627218053?lang=en_us&edition=fundamental","pubTime":"2026-04-16 20:33","pubTimestamp":1776342828,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nFWN40Z0UP:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627187802","title":"Atossa Therapeutics - on April 13, Co Entered Settlement Agreement to Resolve Endoxifen Patent Disputes - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2627187802","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627187802?lang=en_us&edition=fundamental","pubTime":"2026-04-16 20:33","pubTimestamp":1776342828,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nFWN40Z0UP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627218268","title":"Atossa settles Endoxifen patent dispute with Intas, Jina Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2627218268","media":"Reuters","labels":["corporation","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627218268?lang=en_us&edition=fundamental","pubTime":"2026-04-16 20:31","pubTimestamp":1776342704,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics entered settlement agreement April 13, 2026 with Intas Pharmaceuticals, targeting resolution of Endoxifen patent disputes.Deal calls for termination of pending U.S. Patent Trial and Appeal Board proceedings challenging two Atossa patents.Settlement includes mutual non-challenge covenants covering specified Endoxifen-related patents and applications, subject to limited exceptions.Agreement preserves Atossa ability to develop and commercialize Z-endoxifen base in oncology, endocrine dysfunction disorders, muscular dystrophy-related diseases.Upon PTAB termination, Atossa expects patents 11,261,151 and 12,071,391 to remain issued and enforceable against other third parties.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL737kZh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622847966","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2622847966","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622847966?lang=en_us&edition=fundamental","pubTime":"2026-03-27 18:00","pubTimestamp":1774605600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·SBC Med Grp Hld                                  4Q       .12       BMO. ·INmune Bio Inc                                  4Q      (.26)  4:05 PM. ·Banzai Intl Cl A                                4Q      (.59)      AMC. ·FactSet Res Sys                                  2Q      4.38   6:00 AM. ·McCormick & Co                                 1Q       .60   6:30 AM","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APOG","INV","BEEM","HUMA","AEHR","BITF","AYI","KEEL","AIRO","CALM","BCAX","PHR","FDS","NEOG","PLAY","ANGO","BIRD","MKC","AURA","PENG","PRGS","BNZI","JILL","NCNO","NGEN","ATOS","CRDL","MKC.V","CCL","LNN","FC","KOPN","MSLE","NKE","BYND","BTBT","NKLR","RNXT","AIRJ","CAG","LW","INMB","KYTX","DEFT","IMNN","MSM","DMAC","BHST","AUTL","NMRA","LGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622985458","title":"Atossa Therapeutics : H.c. Wainwright Adjusts Target Price to $25 to Reflect 1-for-15 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2622985458","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622985458?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:25","pubTimestamp":1774524332,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40E0ND:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622000835","title":"Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2622000835","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622000835?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:30","pubTimestamp":1774474200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nTUA3M5CNY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622007795","title":"Atossa Therapeutics FY2025 operating loss widens 34% to $(37) million; loss per share widens to $(4.04)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622007795","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622007795?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:22","pubTimestamp":1774473775,"startTime":"0","endTime":"0","summary":"Atossa published an annual report on Form 10-K for the year ended Dec. 31, 2025, reporting no revenue.Net loss was USD 34.8 million, and net loss per share was USD 4.04.Research and development expense rose 50% to USD 21.2 million, driven by higher spending on -endoxifen trials and increased drug development costs.General and administrative expense increased 18% to USD 16.0 million, primarily due to higher legal fees tied to ongoing litigation and patent defense.Cash and cash equivalents were USD 41.3 million at year-end, and management said existing resources are expected to fund planned operations for the next 12 months.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to gen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL1ZxbWN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622007788","title":"Atossa Therapeutics FY2025; R&D expense climbs to $21.2 million; clinical and non-clinical trial expense rises 60% to $16.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622007788","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622007788?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:20","pubTimestamp":1774473658,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics FY2025; R&D expense climbs to $21.2 million; clinical and non-clinical trial expense rises 60% to $16.2 million. -endoxifen is being evaluated in metastatic, neoadjuvant, adjuvant, and breast cancer risk-reduction clinical settings, and it is also being explored for rare diseases including Duchenne muscular dystrophy and McCune-Albright syndrome.In a peer-reviewed publication and scientific presentation, Atossa described a hypothesized therapeutic role for -endoxifen in Duchenne muscular dystrophy, including symptomatic female carriers.The publication outlines potential mechanisms relevant to dystrophic muscle, including estrogen-receptor modulation and allosteric inhibition of PKC-β1.The document does not specify whether any clinical trial results have already been presented or when future results will be presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and tim","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL4GfRZd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621084103","title":"Top News Today/Canada: Bank of Canada to Lose Two Members of Rate-Setting Governing Council","url":"https://stock-news.laohu8.com/highlight/detail?id=2621084103","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621084103?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:30","pubTimestamp":1774297800,"startTime":"0","endTime":"0","summary":"The Bank of Canada said that two members of its rate-setting governing council are departing, and it intends to fill the vacancies internally.The central bank said that Deputy Governor Rhys Mendes would leave on April 10, to relocate to Toronto with his family. He was responsible for the central bank's analysis of international economic developments.Deputy Governor Sharon Kozicki intends to retire on July 15, following a two-decade career at Canada's central bank. She was responsible for overseeing analysis of domestic economic developments.BOC Speech Takes on Heightened Importance Amid Rapid Turn in Rate Expectations. LaGuardia Airport Reopens Hours After Deadly Runway Collision. New York City's LaGuardia Airport was closed Monday after a passenger jet collided with an emergency vehicle on the runway, killing two pilots and injuring dozens of other people.The two pilots of the Air Canada Express plane were killed in the crash shortly before midnight Sunday, and a further 41 people, in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065170008.USD","LU2065169927.USD","INTZ","BK4161","LENZ","BK4007","IE00B19Z4B17.USD","AIR","AIRJ","BK4139","BK4572","KZR","NKTX","BK4104","ATOS","BK4141","BK4187","IE00B7SZL793.SGD","PVL","MXCT","GUTS","BK4023","BK4198","ACHV","LU2065171402.SGD","CNM","KBH","LU2089985449.USD","BK4082","ABSI","CNXC","LU1923621640.USD","BK4539","BRZE","BK4505","BK4135","BK4588","SFES","SMTI","COLFF","LU2125910336.SGD","ECTM","PAYS","SFD","LU2125910179.SGD","BZAI","IE0009354923.USD","EPSN","TIL","BK4213"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621546117","title":"Atossa Therapeutics Inc. Announces Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2621546117","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621546117?lang=en_us&edition=fundamental","pubTime":"2026-03-21 04:53","pubTimestamp":1774040016,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics will hold its annual stockholders meeting as a virtual meeting on May 7, 2026.Items to be voted on include electing three Class II directors: Stephen Galli, Richard Steinhart and Tessa Cigler.Shareholders will also vote on ratifying Ernst & Young as the independent registered public accounting firm.Another proposal seeks approval to amend the certificate of incorporation to allow a reverse stock split at a ratio between 2:1 and 20:1.Additional votes cover an advisory say-on-pay resolution and a proposal to adjourn the meeting if needed to solicit additional proxies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the E","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL8RWMxw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620736426","title":"Atossa Therapeutics Inc  expected to post a loss of $1.14 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2620736426","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620736426?lang=en_us&edition=fundamental","pubTime":"2026-03-20 20:51","pubTimestamp":1774011069,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Inc  expected to post a loss of $1.14 a share - Earnings Preview Atossa Therapeutics Inc ATOS.OQ ATOS.O is expected to  show no change in quarterly revenue when it reports  results","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nL8N40817J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620723247","title":"Atossa Therapeutics appoints Kathy Puyana Theall and Adebola Giwa as medical directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2620723247","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620723247?lang=en_us&edition=fundamental","pubTime":"2026-03-19 20:04","pubTimestamp":1773921851,"startTime":"0","endTime":"0","summary":"Atossa engaged Kathy Puyana Theall as Medical Director - Breast Oncology and Adebola Giwa as Medical Director - Rare Diseases.Kathy Puyana Theall previously served as Vice President of Clinical Development - Breast Cancer at Stemline-Menarini.She also held senior roles at Pfizer and worked in academic medicine at Tufts Medical Center.Adebola Giwa most recently served as Senior Medical Director at Maze Therapeutics.He previously held roles at Angitia Biopharma and Ascendis Pharma, and founded AdeBolus Medical Consulting.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL5c6j94:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1066053197.SGD","BK4559","LU1066051498.USD","LU0306806265.USD","LU0130517989.USD","LU0868494617.USD","ATOS","LU0109394709.USD","LU0320765992.SGD","LU0985481810.HKD","BK4533","BK4581","LU0889565916.HKD","SG9999013999.USD","LU0225771236.USD","IE0002270589.USD","BK4550","BK4599","LU0170899867.USD","LU0289739699.SGD","LU1023059063.AUD","BK4534","BK4007","LU0130102774.USD","LU1883839398.USD","LU0234572021.USD","SG9999003800.SGD","SG9999011175.SGD","LU0321505868.SGD","IE00B19Z3B42.SGD","LU0477156953.USD","LU1699723380.USD","IE00BLSP4452.SGD","LU0321505439.SGD","LU1894683264.USD","BK4588","SG9999002224.SGD","LU0122379950.USD","SG9999001176.USD","LU1894683348.USD","BK4568","SGXZ57979304.SGD","BK4139","BK4592","LU0225284248.USD","LU0306807586.USD","IE00BBT3K403.USD","IE000M9KFDE8.USD","LU0058720904.USD","LU0648001328.SGD","LU0980610538.SGD","LU1201861249.SGD","LU0456855351.SGD","IE00BLSP4239.USD","SG9999002232.USD","LU1571399168.USD","LU1057294990.SGD","IE00B19Z3581.USD","SG9999001176.SGD","BK4135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620471642","title":"Atossa Therapeutics Strengthens Clinical Leadership Team With the Addition of Two Experienced Biopharma Executives","url":"https://stock-news.laohu8.com/highlight/detail?id=2620471642","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620471642?lang=en_us&edition=fundamental","pubTime":"2026-03-19 20:00","pubTimestamp":1773921604,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nTUA9RPDSS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618113102","title":"Atossa Therapeutics reports (Z)-endoxifen improved muscle performance in mdx5Cv Duchenne muscular dystrophy mice","url":"https://stock-news.laohu8.com/highlight/detail?id=2618113102","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618113102?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:06","pubTimestamp":1773317198,"startTime":"0","endTime":"0","summary":"Atossa presented an oral clinical trial update on -endoxifen at the MDA Clinical & Scientific Conference. The update included preclinical results from the mdx5Cv dystrophic mouse model used in Duchenne muscular dystrophy research. Atossa reported that -endoxifen improved muscle strength and motor performance in juvenile and adult mice. The company also reported reduced biochemical and histologic markers of muscle damage, and no adverse findings observed during the study.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL7GrfHp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613297697","title":"Atossa Therapeutics:  Entered Into at Market Offering Agreement to Sell Shares Our Common Stock of up to $50,000,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2613297697","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613297697?lang=en_us&edition=fundamental","pubTime":"2026-02-21 05:18","pubTimestamp":1771622325,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nFWN3ZG112:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610953582","title":"BRIEF-Atossa Therapeutics Issues Letter To Shareholders Highlighting 2025 Accomplishments And 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2610953582","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610953582?lang=en_us&edition=fundamental","pubTime":"2026-02-11 21:58","pubTimestamp":1770818307,"startTime":"0","endTime":"0","summary":"BRIEF-Atossa Therapeutics Issues Letter To Shareholders Highlighting 2025 Accomplishments And 2026 OutlookFeb 11 (Reuters) - Atossa Therapeutics Inc ATOS.O:ATOSSA THERAPEUTICS ISSUES LETTER TO SHAREHO","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA40SL1Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610495854","title":"Atossa Therapeutics Completes Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2610495854","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610495854?lang=en_us&edition=fundamental","pubTime":"2026-02-11 21:31","pubTimestamp":1770816665,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Inc. has completed a reverse stock split, effective February 2, 2026. The move is intended to help the company regain compliance with Nasdaq listing requirements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on February 11, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDLc87dWQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610379958","title":"Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2610379958","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610379958?lang=en_us&edition=fundamental","pubTime":"2026-02-11 21:30","pubTimestamp":1770816601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA40SL1Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.atossatherapeutics.com;investors.atossatherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":0.0517},{"period":"3month","weight":-0.4082},{"period":"6month","weight":-0.5924},{"period":"1year","weight":-0.4813},{"period":"ytd","weight":-0.3559}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.087},{"period":"3month","weight":0.0359},{"period":"6month","weight":0.0542},{"period":"1year","weight":0.3059},{"period":"ytd","weight":0.047}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.269844},{"month":2,"riseRate":0.5,"avgChangeRate":0.058135},{"month":3,"riseRate":0.428571,"avgChangeRate":0.091975},{"month":4,"riseRate":0.357143,"avgChangeRate":-0.034083},{"month":5,"riseRate":0.384615,"avgChangeRate":-0.014461},{"month":6,"riseRate":0.615385,"avgChangeRate":0.128869},{"month":7,"riseRate":0.230769,"avgChangeRate":-0.109234},{"month":8,"riseRate":0.307692,"avgChangeRate":-0.058495},{"month":9,"riseRate":0.307692,"avgChangeRate":-0.023021},{"month":10,"riseRate":0.153846,"avgChangeRate":-0.183809},{"month":11,"riseRate":0.307692,"avgChangeRate":-0.054625},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.125403}],"exchange":"NASDAQ","name":"Atossa Genetics","nameEN":"Atossa Genetics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Atossa Genetics(ATOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Atossa Genetics(ATOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Atossa Genetics,ATOS,Atossa Genetics股票,Atossa Genetics股票老虎,Atossa Genetics股票老虎国际,Atossa Genetics行情,Atossa Genetics股票行情,Atossa Genetics股价,Atossa Genetics股市,Atossa Genetics股票价格,Atossa Genetics股票交易,Atossa Genetics股票购买,Atossa Genetics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Atossa Genetics(ATOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Atossa Genetics(ATOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}